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Abstract: Community-acquired pneumonia (CAP) places a considerable burden on society.
A substantial number of pediatric and adult CAP cases are due to Streptococcus pneumoniae, but
fortunately there are effective vaccines available that have a significant impact on CAP-related
medical, social, and economic problems. The main aim of this paper is to evaluate the published
evidence concerning the impact of pneumococcal vaccines on the prevention of CAP in children and
adults. Available data indicate that pneumococcal conjugate vaccines (PCVs) are effective in children,
reducing all-cause CAP cases and bacteremic and nonbacteremic CAP cases. Moreover, at least for
PCV7 and PCV13, vaccination of children is effective in reducing the incidence of CAP among adults.
Recently use of PCV13 in adults alone or in combination with the pneumococcal polysaccharide
vaccine has been suggested and further studies can better define its effectiveness in this group of
subjects. The only relevant problem for PCV13 is the risk of a second replacement phenomenon,
which might significantly reduce its real efficacy in clinical practice. Protein-based pneumococcal
vaccines might be a possible solution to this problem.
Keywords: community-acquired pneumonia; pneumococcal conjugate vaccine; pneumococcal
polysaccharide vaccine; pneumococcal prevention
1. Introduction
Community-acquired pneumonia (CAP) is a common infectious condition in any period of
life, with higher impact in resource-limited than industrialized countries [1]. The World Health
Organization (WHO) reports >150 million CAP cases each year in children <5 years old, leading to
0.29 episodes per child-year, 20 million hospitalizations, and approximately 2 million child deaths [2].
In industrialized countries, the total number of CAP cases is approximately 4 million, with an incidence
of 0.05 episodes per child-year [2–4]. Mortality rate is <1 per 1000 per year, with higher values only in
subjects with severe chronic underlying diseases [2–4]. In adults, it was shown that lower respiratory
tract infections (including CAP) are the fourth most common cause of death globally and the second
most frequent reason for years of life lost [5]. Within Europe, a recent study has demonstrated an overall
annual incidence of 1.07 to 1.2 per 1000 person-years and from 1.54 to 1.7 per 1000 population; incidence
further increased with age (14 per 1000 person-years among adults aged ≥65 years) [6].
All the aforementioned reasons explain the burden of CAP on society and the importance of
methods able to reduce its incidence and impact [7].
A substantial number of pediatric and adult CAP cases are due to Streptococcus pneumonia
(S. pneumoniae) [8,9], but fortunately there are effective vaccines available that are likely to have
a significant impact on CAP-related medical, social, and economic problems [10]. This manuscript
aims to study the impact of pneumococcal vaccines on the prevention of CAP in children and adults.
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2. Pneumococcal Vaccines
Two different pneumococcal vaccines are available in the market: polysaccharide vaccines (PPVs)
and conjugate vaccines (PCVs) [11]. In PPV, capsular polysaccharides are purified, but not too much
modified, with antigens that remain T-cell independent, whereas the capsular polysaccharides in
PCVs are conjugated with a carrier protein and the antigens become T-cell dependent. The majority of
the studies comparing the immunogenicity of the two vaccines have shown that PCVs have higher
humoral immunogenicity and induce a stronger cell-mediated immunity mainly in younger children
who are unable to respond to T-independent antigens [12].
The 23-valent PPV (PPV23) is the only PPV currently marketed. It contains 23 serotypes (i.e., 1, 2,
3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F) [13].
Different PCVs including various numbers of serotypes (i.e., 7, 9, 10, 11 and 13) and various
carrier proteins have been evaluated, but only PCV10 (containing serotypes 1, 4, 5, 6B, 7F, 9V, 14,
18C, 19F and 23F) [14] and PCV13 (containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F,
23F) [15] are currently marketed. These two vaccines have different types of carrier proteins: in PCV10,
eight capsular polysaccharides are conjugated to a non-lipidated cell surface lipoprotein (protein D) of
non-typeable Haemophilus influenzae, and two capsular polysaccharides are conjugated to tetanus or
diphtheria toxoid; in PCV13, all serotypes are conjugated to CRM197, a nontoxic mutant of diphtheria
toxin. PCV13 replaced PCV7, which included serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F and was
used in the first 10 years of this century but was subsequently withdrawn from the market when it
became clear that there was a need for vaccines with more pneumococcal serotypes [16], although with
a similar immunogenicity [17,18].
Both PCV10 and PCV13 are licensed for use in children from 6 weeks to 5 years of age for
prevention of invasive pneumococcal disease (IPD), CAP and otitis media. However, PCV13 has also
been licensed for use in older subjects.
3. Pneumococcal Vaccine Prevention of CAP in Children
PPV23 is recommended in the USA against infections due to S. pneumoniae in children >2 years
old with severe chronic underlying diseases associated with an increased risk of complications due
to pneumococcal infection [19]. Despite this recommendation, data concerning CAP prevention in
pediatric patients have been obtained in children vaccinated with a PCV. Most of the studies in
this regard were performed during the period in which PCV7 was used, although recently some
epidemiological evaluations carried out after the introduction of PCV10 and PCV13 have reported
reliable information on the impact of these new preparations. A systematic comparison of the results of
these studies is problematic because of the considerable variations of vaccination schedules, endpoints
chosen, population studies, and methodological key points. However, available data indicate that
all of the PCVs are significantly effective in reducing the hospitalization rate for all-cause CAP, the
incidence of pneumococcal CAP and the risk of death from CAP in vaccinated children, although
the impact is different according to the type and number of included serotypes [20–40]. Moreover, at
least for PCV7, there is clear evidence that the use of the vaccine induces a significant indirect effect,
reducing CAP incidence in unvaccinated adults [20–25]. Furthermore all suggested schedules of PCV
administration yield positive results [41–45], and all PCVs are safe and well tolerated [41–54].
4. Heptavalent Pneumococcal Conjugate Vaccine (PCV7)
Several studies, mainly carried out in the USA where PCV7 was implemented in 2000 and the
3 + 1 schedule was used, have evaluated the impact of PCV7 on CAP. Among them, of relevance are
the studies carried out by Griffin et al. [20] and Grijalva et al. [21], in which an accurate case definition
was used and a long study period was considered. Children <2 years old who were given PCV7
were the subjects who received the greatest benefit from vaccination. However, the benefit tended to
decline with increasing age. In particular, Griffin et al. found declines in CAP hospitalization rates of
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approximately 40% in children <2 years and 12.2% in children aged 2–4 years but not in children aged
5–17 years [20].
Further data showing the positive impact of PCV7 immunization on CAP of both children
and adults were reported by Simonsen et al. [22]. Those authors assessed the impact of PCV7 on
pneumococcal CAP hospitalization and mortality in all age groups using complete hospitalization data
of 10 states in the USA. Compared to a baseline of 1996–1997 through 1998–1999, by the 2005–2006
season, pneumococcal CAP hospitalization and deaths were found to have decreased substantially
in all age groups, including a 47% (95% confidence interval (CI) 38–54) reduction in nonbacteremic
pneumococcal CAP in infants <2 years old and a 54% reduction (95% CI 53–56) in adults ≥65 years of
age. A model developed to calculate the total burden of pneumococcal CAP prevented by infant PCV7
vaccination in the USA from 2000 to 2006 estimated a reduction of 788,838 (95% CI 695,406–875,476)
hospitalizations [22]. Ninety percent of the reduction occurred among adults; similar proportions were
found in pneumococcal disease mortality prevented by the vaccine. Moreover in the first seasons
after PCV introduction, when there were substantial state differences in coverage among <5-year-olds,
states with greater coverage had significantly fewer influenza-associated CAP hospitalizations among
children, suggesting that PCV7 use could also reduce influenza-attributable CAP hospitalizations.
Finally a significant decline in RSV-coded hospitalizations in children aged <1 year was observed
following PCV7 introduction (−18.0%, 95% CI: −22.6%, −13.1%, for 2004/2005–2008/2009 versus
1997/1998–1999/2000) [23].
The effectiveness of PCV7 was also evidenced in Europe. In the UK, where PCV7 was added to
the national immunization program in September 2006, the incidence of all-cause CAP in 2008–2009
was 11.8/10,000 (95% CI 10.9–12.9), and the hospitalization rate was 9.9/10,000 (95% CI 9.0–10.9) [24].
Compared to 2001, there was a 19% (95% CI 8–29) reduction in the rate of CAP in those aged <5 years,
a 33.1% (95% CI 20–45) reduction in the incidence of CAP in those <2 years, and a 38.1% (95% CI
24–50) reduction in hospitalization rates. However for those unvaccinated aged ≥5 years, there was
no difference in the incidence of CAP and the hospitalization rate between both surveys.
Despite these and other favorable results, the PCV7 vaccine was abandoned worldwide in
2010 and substituted with new vaccines (PCV10 and PCV13) containing, together with serotypes
included in PCV7, some serotypes that, after PCV7 implementation, have emerged as a main cause
of pneumococcal disease, slightly but significantly eroding the global impact of the first PCV on
IPD [16]. Regarding CAP, it was evidenced that the impact of the replacement phenomenon was
limited. Griffin et al. showed that the number of CAP cases in the first 2 years of life and in the age
group 2–4 years decreased after the introduction of PCV7, thus limiting concerns that CAP cases
caused by serotype replacement would significantly limit the advantage of vaccination [20]. However
PCV7 seemed to have a considerable effect on severe CAP because there was an increase in necrotizing
CAP and parapneumonic empyema due to serotypes 1, 3 and 19A, which are more likely to cause
necrotising CAP [25].
5. 10-Valent Pneumococcal Conjugate Vaccine (PCV10) and 13-Valent Pneumococcal Conjugate
Vaccine (PCV13)
Epidemiological studies have provided evidence that the new preparations were both effective
and safe and could be administered for the prevention of IPD and CAP. Presently it is impossible to
state whether there are differences between PCV10 and PCV13 in the prevention of pediatric CAP.
The first results of PCV10 administration were collected in Brazil where the vaccine was
introduced in 2010 with a 3 + 1 schedule [26]. Hospitalization rates for CAP among children aged
2–24 months from January 2005 through August 2011 were analyzed. A 23%–29% decline in 3 of
5 cities included in the study one year after the implementation of PCV10 was found. Positive data
on CAP incidence following PCV10 implementation were also reported in a study carried out in
Chile [27]. This vaccine was introduced in that country in January 2011 with a 3 + 1 schedule without
a catch-up vaccination. A population-based nested case-control study using a number of merged
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nationwide case-based electronic health data registries measured the effectiveness of PCV10 on CAP
morbidity and mortality among infants during the first two years after vaccine introduction. A total of
497,996 children were included. The PCV10 effectiveness was 11.2% (95% CI 8.5–13.6) when all CAP
hospitalizations and deaths were used to define cases [27]. However the effectiveness increased to
20.7% (95% CI 17.3–23.8) when codes used to identify viral CAP were excluded. Finally effectiveness
estimates of pneumonia death and all-cause death were 71.5% (95% CI 9.0–91.6) and 34.8% (95% CI
23.7–44.4), respectively.
A number of studies have analyzed the impact of PCV13 on CAP. In Nicaragua, PCV13 was
introduced in December 2010 with a 3 + 0 schedule. Becker-Dreps et al. reported that in that country, the
adjusted incidence rate ratio for CAP hospitalization in the vaccine (2011–2012) versus the pre-vaccine
(2008–2010) period was 0.67 (95% CI 0.50–0.75) among infants and 0.84 (95% CI 0.74–0.95) among
1-year-old children [28]. Moreover lower rates of health facility visits for CAP among age groups
ineligible to receive PCV13 (2 to 4 years old and 5 to 14 years old) were evidenced, providing evidence
of herd immunity.
The impact of sequential PCV7 and PCV13 was studied in the USA, where, 2 years after
introduction, PCV13 was associated with significant reductions in hospital admissions for all-cause
CAP for some children (21%, 95% CI 14–28 in children aged <2 years; 17%, 95% CI 7–27 in those aged
2–4 years) and for empyema (50%, 95% CI 22–68, for children aged <2 years; 46%, 95% CI 21–64, for
2–4 years; 37%, 95% CI 13–54, for 5–17 years) [29]. All-cause pneumonia was significantly reduced
in adults aged 18–39 years (12%, 95% CI 6–17) but not for other adult age groups. The vaccine also
reduced admissions for invasive pneumococcal CAP and non-invasive pneumococcal or lobar CAP in
children and adults, indicating herd protection, although the reduction was significant only in some
age groups [29]. Similar positive results were reported by Greenberg et al. in Israel [30]. In that country,
PCV7 was introduced in July 2009 and was gradually replaced by PCV13 in November 2010. The PCV
impact on the incidence of alveolar CAP, considered a bacterial disease, mainly due to S. pneumoniae,
was calculated by comparing the incidence of disease in 3 predefined periods: pre-PCV (2002–2008),
PCV7 (2010–2011), and PCV13 (2012–2013). The annual incidence of alveolar CAP per 1,000 inhabitants
in children <5 years declined from a mean of 13.8 in the pre-PCV period to 11.2 and 7.4 in the PCV7
and PCV13 periods, respectively [30]. The reduction in the alveolar CAP rate in the PCV7 period was
mainly observed in outpatients and was more marked in children 12–23 months of age, but in the
PCV13 period the rates declined significantly in all age groups among both outpatients and inpatients.
A comparison between the impacts of PCV10 and PCV13 was made by Berglund et al. in
Sweden [31]. In that country, PCV7 was implemented in 2009. By 2010, both PCV10 and PCV13 were
licensed, and the selection of the vaccine was subject to the County Councils tenders. The introduction
of PCV-7 reduced the likelihood of all-cause CAP hospitalizations by 23% among children aged
<2 years. In the counties that have substituted PCV7 with PCV13, a trend to a further 18% decrease was
observed. On the contrary, where PCV10 was privileged no further decline was reported, suggesting
a potential superiority of PCV13 over PCV10 in the prevention of pediatric CAP. Unfortunately
the study has some limitations, mainly related to the short time of use of PCVs before evaluation.
Herd effects are maximized after only 5–7 years of PCV use and in this study the PCV7 period took
only 3 years. Consequently definitive conclusions cannot be drawn. Moreover, lacking data regarding
serotypes involved in CAP etiology, it is impossible to state whether this difference must be ascribed
to the higher serotype coverage of PCV13 or other undetermined factors.
However, a recent cost-effectiveness analysis of PCVs in preventing CAP in Peruvian children
aged <5 years seems to further suggest the superiority of PCV13 [32]. It was shown that PCV10 and
PCV13 are more cost-effective than PCV7, but PCV13 prevented more hospitalizations and was more
cost-effective than PCV10. Costs per avoided hospitalization were ESD 718 for PCV7, 333 for PCV10,
and 162 for PCV13. Finally different serotype composition may play a role in favor of PCV13. This PCV
contains serotype 3 and 19A, which are not included in PCV10 and are two of the most common
causes of severe CAP and empyema [33]. The importance of serotype 3 is debated. Undoubtedly
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putative protective levels for this serotype are very high and not achieved in a number of vaccinated
subjects [34]. However significant reduction in the risk of IPD due to serotype 3 in children who have
received PCV13 has been demonstrated. Considering that protection against CAP probably needs
higher antibody concentrations than those needed for IPD prevention, it is likely that a number of
cases of this disease associated with serotype 3 infection can occur despite vaccination. It seems to be
confirmed by the evidence that in recent years several cases of severe CAP in children vaccinated with
PCV13 have been reported [35,36].
Regarding serotype 19A, antibody levels and function after PCV13 have been found significantly
higher than those measured after PCV10 [37]. This could lead to greater protection. On the other hand,
while introduction of PCV13 has worldwide led to a significant reduction of the 19A pneumococcal
infections [38] and carriage [39], this was not always seen after PCV10 use [33]. A clear example
of the poor effectiveness of PCV10 against serotype 19A infection is given by the evidence that in
New Zealand, where PCV10 was introduced in October 2011, the number of 19A IPD cases reported
in the years following PCV10 use was higher than in the years before, leading health authorities of
that country to replace PCV10 with PCV13 [40]. However available data and theoretical suggestions
must be reevaluated and confirmed, considering also the impact of the replacement phenomenon and
vaccine cost, because these factors can be of relevance when making decisions about the choice of the
PCV to include in national immunization schedules worldwide.
6. Impact of Different Pneumococcal Conjugate Vaccine (PCV) Schedules
All PCVs are usually administered in the first year of life with a primary series of two or three
doses given in the first semester of life with a booster dose at approximately one year (i.e., 3 + 1
and 2 + 1 schedules) [41]. A schedule including 3 doses as primary series without a booster dose
(3 + 0 schedule) has also been suggested [41]. In children with a severe underlying condition at risk
of invasive pneumococcal disease, a booster of PCV13 is recommended between 2 and 6 years of
age [41]. Moreover the same vaccine should be administered to at-risk children aged 6–18 years
with no history of PCV13 vaccination [41]. As previously mentioned, all suggested immunization
schedules are effective in clinical practice. This is well documented by the recent study by Loo et al. [42].
Those authors reviewed studies published from 1994 to 2011 that documented the effects of PCV7
in children of the ages targeted to receive the vaccines. Studying the results of the studies according
to the schedule used, they found that the 3 + 1 schedule and the simplified schedules 3 + 0 or
2 + 1 all decrease all-cause CAP [42]. However these data support the WHO recommendation of
3-dose schedules (3 + 0 or 2 + 1) to limit the cost of vaccination and favor compliance in prevention of
pneumococcal disease [43]. In resource-limited countries, where the highest incidence of pneumococcal
disease and deaths occur before the end of the first year of life, a schedule of early PCV doses (3 + 0
schedule) seems the best solution; in other countries, a schedule with a booster dose may be better
against diseases that peak in the second year of life. Whitney et al. [43] showed that the simplified
2 + 1 schedule is the best compromise between effectiveness and cost [44,45].
7. Safety and Tolerability of Pneumococcal Conjugate Vaccines (PCVs)
All PCVs are safe and well tolerated [41]. The only problem that emerged during the PCV7 use
was the increased risk of severe lung disease, particularly with lung necrosis and parapneumonic
empyema [25,44–50]. Grijalva et al. showed that parapneumonic empyema increased from 3.5 cases
per 100,000 children in 1996–1998 to 7.0 cases per 100,000 children in 2005–2007, with the highest
increase among children aged 2–4 years [44]. Thomas et al. observed that, although pneumococcal
empyema rates remained relatively stable, the roles played by serotypes 1, 3 and 19A significantly
increased and they were found in more complicated diseases [45]. Similar results were reported by
Byington et al. in the USA [46].
However, although important, emerging pneumococcal serotypes are not the only factors
that explain the increase in parapneumonic empyema after the inclusion of PCV7 in the pediatric
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immunization program. Grijalva et al. observed that a high number of cases in children 2–4 years
old were due to streptococci other than S. pneumoniae and Staphylococcus aureus (S. aureus), the
rates of which increased by 2.80 and 3.76 times respectively, after the introduction of PCV7 [44].
An increase in S. aureus in patients with CAP and empyema has been observed [51]. It has been
shown that this may be related to the use of PCV7 because, by inducing a significant reduction in
pneumococcal nasopharyngeal colonization for some months, it can favor a temporary increase in
S. aureus colonization and related diseases [52]. It has been highlighted that the vaccine may disrupt
S. pneumoniae advantage, which interferes with S. aureus colonization by limiting the resources available
for its multiplication [53]. However recent epidemiologic evaluations seem to indicate that the risk of
empyema development was not increased after introduction of PCV13 [54].
8. Vaccine Prevention of Community-Acquired Pneumonia (CAP) in Adults
For more than 2 decades, the prevention of pneumococcal CAP in adults has been based on the
administration of PPV23. It was licensed in 1983 to replace an earlier 14-valent formulation without any
prelicensure trial evaluating its efficacy against bacteremic pneumonia [13]. Since its introduction on
the market in the USA, PPV23 has been recommended for adults≥65 years. Through 2012, a single dose
of PPV23 has been recommended for subjects <65 years old with chronic medical conditions including
immunodeficiencies and adults with asthma or who smoke cigarettes [55]. A single re-vaccination with
PPV23 five years after the initial dose was recommended before age 65 years for adults with immune
compromise or those with functional or anatomic asplenia. In addition, a single dose of PPV23 was
recommended for all adults ≥65 years old regardless of previous history of PPV23 [55].
Considering the aforementioned immunological limitations of PPV23, in an effort to protect
individuals at risk, immunization with this vaccine should be repeated every 5 years. However the
repeated use of PPV23 has been associated with hyporesponsiveness, a phenomenon already described
following vaccination with meningococcal polysaccharide vaccines [56,57]. This hyporesponsiveness
is characterized by the inability of the re-vaccinated subject to mount an antibody production of at
least the same magnitude as the primary response and is ascribed to the immune tolerance induced
by the polysaccharide antigens [58–61]. The magnitudes of hyporesponsiveness seem to differ among
pneumococcal serotypes and are related to the number of doses and the intervals between subsequent
vaccinations [62]. More than two doses and shortened intervals between vaccinations, particularly in
individuals with high levels of circulating antibodies, are associated with a higher risk of reduced antibody
production [63]. For these reasons, no more than 2 doses of PPV23, 5 years apart, are recommended.
Despite these immunological problems, PPV23 has been largely used in clinical practice mainly
for the prevention of IPD and CAP in adults. Data regarding IPD were satisfactory because they
were consistent with significant protection among generally healthy young adults and among the
general population of older adults. For example, in a recent meta-analysis of the studies published
before August 2015 that independently evaluated the impact of PPV23 in the general population aged
50 years and older, it was shown that the vaccine effectiveness in preventing IPD, including bacteremic
CAP, was 50% (95% CI 21–69) for cohort studies and 54% (95% CI 32–69) for case-control studies [64].
However, data regarding efficacy in nonbacteremic CAP, the most common type of pneumococcal
CAP, are contradictory. The meta-analysis by Moberley et al. evidenced efficacy against all-cause
CAP in low-income (OR 0.54, 95% CI 0.43–0.67) but not high-income countries in either the general
population (OR 0.71, 95% CI 0.45–1.12) or in adults with chronic illness (OR 0.93, 95% CI 0.73–1.19) [53].
Conflicting results were also obtained by Huss et al. [52]. When all available studies were considered,
those authors found that PPV23 was effective in reducing the risk of presumptive pneumococcal CAP
and all-cause CAP (relative risk (RR) 0.64, 95% CI 0.43–0.96, and 0.73, 95% CI 0.56–0.94, respectively).
However when only trials of higher methodologic quality were analyzed, no evidence of vaccine
protection was demonstrated (RR 1.20, 95% CI 0.75–1.92, for presumptive pneumonia; and 1.19, 95%
CI 0.95–1.49, for all–cause pneumonia) [52].
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The marginal effect of PPV23 on CAP prevention was described by Kraicer-Melamed et al., who
reported for a global population a vaccine effectiveness for CAP of 4% (95% CI −26 to 26) for trials,
17% (95% CI −26 to 45) for cohort studies, and 7% (95% CI −10 to 21) for case-control studies [64].
Conversely a positive effect of PPV23 was reported by other meta-analyses. Among them, one of
the most recent was carried out by Diao et al. [65], who reported a weak association between PPV23
administration and prevention of all-cause CAP (RR 0.87, 95% CI 0.76–0.98), especially in individuals
aged >65 years and high-risk subjects aged 19–64 years (RR 0.72, 95% CI 0.69–0.94) [65]. Moreover,
protective trends of PPV23 in the outcomes of pneumococcal CAP (RR 0.54, 95% CI 0.18–1.65) and
mortality due to CAP (RR 0.67, 95% CI 0.43–1.04) were observed.
Practically, convincing evidence that PPV23 can protect adults from CAP is lacking. To provide
definitive protection of adults against CAP, the combined use of PPV23 and PCV13 was suggested.
Updated guidelines prepared by the Advisory Committee on Immunization Practices (ACIP) for
pneumococcal vaccination in adults recommend that pneumococcal vaccine naïve subjects receive
PCV13 in series with PPV23 with a time interval of at least one year between doses [5]. The rationale
for the association and the sequence was based on immunogenicity studies because no clinical studies
evaluating the efficacy of the two vaccines given in series are available. With few exceptions, a single
dose of PCV7, the first conjugate pneumococcal vaccine, was generally found able to evoke a higher
immune response than a single dose of PPV23, in both immunocompetent and immunocompromised
adults [61,66–69]. Moreover it was evidenced that initial vaccination with PCV13 established an immune
state that results in recall anti-pneumococcal responses upon subsequent vaccination with either PCVs
or PPV23. In contrast, initial vaccination with PPV23 results in an immune state in which subsequent
PPV23 administration yields generally lower responses compared with the initial responses [70,71].
The length of the interval between PCV13 and PPV23 is not definitively established, although some data
seem to indicate that a long interval may be required to optimize the immune response to the second
immunization after an initial dose of PCV. A comparison of antibody responses after a PCV13-PPSV23
sequence to responses following PCV13 or PPSV23 alone, across two studies with intervals of 1 year and
3–4 years between the two vaccines, indicated that the responses to many serotypes are improved with
a 3–4-year interval compared with a 1-year interval [70,71]. However, together with immunogenicity,
other factors must be considered when a distance between doses must be established [72]. First of
all, practical aspects related to health-seeking behavior of adults to minimize missed opportunities
for vaccination must be considered. Moreover the different distributions of pneumococcal serotypes
that cause disease according to age might be relevant. A non-negligible amount of pneumococcal
infections in adults aged ≥65 years is due to serotypes unique to PPV23 that seem to be less common
among younger adults [73]. This could lead to a reduced interval in the oldest individuals and the
establishment of longer intervals for younger adults. Moreover, safety reasons can lead to maintaining
longer intervals. One study that has compared 2- versus 6-month intervals between PCV13 and PPV23
showed an increased risk of reactogenicity in the group of individuals with close vaccinations [74].
However the use of PCV13 as the first measure to prevent CAP in adults is supported by a recently
performed study [75]. A randomized, double-blind, placebo-controlled study named CAPITA
(Community-Acquired Pneumonia Immunization Trial in Adults) evaluated the efficacy of PCV13
in preventing the first episodes of vaccine-type strains of pneumococcal CAP, nonbacteremic and
noninvasive CAP, and IPD. The study included 84,496 pneumococcal vaccine naïve immunocompetent
adults ≥5 years, and the enrolled subjects were followed for an average of approximately 4 years.
The vaccine efficacy was found to be 46% in the prevention of first episode vaccine-type CAP, 45%
in first episode nonbacteremic and noninvasive vaccine-type CAP, and 75% in vaccine-type IPD.
PCV13 was also found to be safe in the studied population, although there were more local reactions
and systemic events in the PCV13 group compared to the placebo. Additional endpoints observed
during the study included the first episode of nonbacteremic and noninvasive pneumococcal CAP
including non-vaccine serotypes and first episode of all-cause CAP. PCV13 efficacy was not found to
be statistically significant in either of these groups.
Int. J. Mol. Sci. 2017, 18, 30 8 of 13
A dose of PCV13 is recommended also for adults that were already given a dose of PPV23.
Even in this case, the addition of PCV13 assured higher immune system stimulation with final
anti-pneumococcal opsonophagocytic activity titers that were significantly higher for 10 of the
12 common serotypes than those evoked by a second PPV23 administration, although they were
generally lower than those obtained when the first vaccination is carried out with PPV23 [55].
However, according to several experts, the inclusion of PCV13 in the immunization schedule
of adults remains debatable. The CAPITA study was criticized because funding and support were
provided by the manufacturer of PCV13, the study was conducted within one country in a population
with little variation in race, and the enrolled subjects were pneumococcal vaccine naïve. Moreover it
does not clarify whether PCV13 alone can be as effective as the sequential administration of PCV13
and PPV23 or whether the administration of PCV13 after PPV23 really increases the efficacy of
the polysaccharide vaccine [76]. Finally the cost-effectiveness of PCV13 for adults was debated.
Considering the results of the study, it was calculated that the required number of subjects aged
≥65 years to be treated to prevent one case of CAP over 3.97 years would be 1030, without any
mortality benefit and with very high economic costs [77]. On the other hand, it is possible that the
number needed to be treated may be smaller (i.e., the number of preventable infections may be higher)
considering the limitations of the study and the fact that the trial population was not representative of
the population older than 65 years of age, that at the highest risk of pneumococcal CAP. However the
CAPITA trial was designed to estimate vaccine efficacy, whereas to estimate the cost-benefit profile of
a vaccine it is mandatory to perform cost-effectiveness analyses [78].
The most important observation regarding the impact of PCV13 in adults rises from the
demonstrated herd effect of PCV administration. However, with some exceptions, the use of PCV7 in
children was followed by a significant reduction of incidence of both bacteremic and nonbacteremic
CAP in adults. Similar results were evidenced after PCV13 introduction [79,80]. These data suggest that
if the indirect effects of PCV13 administered to children continue to reduce the burden of vaccine-type
disease among adults, the benefit of vaccinating adults with PCV13 is likely to be reduced substantially.
The widespread use of PCV7 has almost completely eliminated infections due to serotypes included
in the vaccine, and it is highly likely that the same reduction may occur after some years of PCV13
use. A significant reduction in IPD caused by most serotypes included in PCV13 across all age groups
has been reported after 3 years of extensive PCV13 use among children [81]. If PCV13 serotypes
will become no longer important as a cause of both bacteremic and nonbacteremic CAP, PCV13
administration in adults might become practically useless despite relevant social and economic costs.
Stoecker et al. reported that for a cohort of 65-year-old in 2013, the cost of adding PCV13 to the
schedule was $62,065 per quality-adjusted life year gained, which rose to $272,621 after 6 years of
projected herd protection [82]. This explains why ACIP, in the recommendations for the use of both
PCV13 and PPV23, highlights that these recommendations are provisional and must be reevaluated, if
needed, in 2018 [55]. In the meantime, the impact of PCV13 and PPV23 on CAP incidence in adult
populations should be accurately monitored, and adequately planned studies should be carried out to
measure the real importance of PCV13 introduction.
9. Conclusions
Available data indicate that PCVs are effective in children, reducing all-cause CAP cases and
bacteremic and nonbacteremic CAP cases. Moreover, at least for PCV7 and PCV13, an impact on CAPs
among adult people is demonstrated. The only relevant problem for PCV13 is the risk of a second
replacement phenomenon, similar to that already reported for PCV7, that might significantly reduce its
real efficacy in clinical practice. Protein-based pneumococcal vaccines might be a possible solution for
this problem [83]. Unfortunately they will only become available for several years. In the meantime,
PCVs must be maintained in the immunization schedule of infants and children and also used to
assure protection among older children with risk factors.
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Significantly less optimistic is the protection of adult people, particularly those aged ≥65 years
with PPV23 alone or in association with PCV13. Real effectiveness of PCV13 and PPV23 in prevention
of adult CAP is not precisely defined. It is not clarified whether sequential administration of the two
vaccines is significantly more effective than a single administration. Moreover the interval between the
two injections is not precisely defined. In addition, the cost-effectiveness of PCV13 use, alone or in
combination, must be better established [84].
Further studies in this regard are urgently needed and ACIP’s decision to reevaluate the present
recommendations in 2018 in light of new epidemiological evaluations and ad hoc studies seems
particularly wise.
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